A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Clinical trial NCT06926868 · RECRUITING
Trial details
- NCT number
- NCT06926868
- Sponsor
- Bristol-Myers Squibb
- Status
- RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-09-11
- Primary completion
- 2028-03-13
- Enrollment
- 600
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.